Pharma BD Deal Intelligence

Pharmanovia / Impact Therapeutics, Inc.

2026 · Licensing/Option · Complete

On 2026-07-31 IMPACT Therapeutics granted Pharmanovia exclusive rights to manufacture, develop and commercialise the PARP inhibitor senaparib across 66 countries in Europe, the Middle East and North Africa, Australia and New Zealand. The lead indication is first-line maintenance monotherapy for advanced epithelial high-grade ovarian, fallopian tube and primary peritoneal cancer; the EMA accepted the marketing authorisation application in August 2025. IMPACT is eligible for an undisclosed upfront plus regulatory and sales milestones totalling up to EUR 423.5 million, and tiered royalties up to the mid-twenties percent. USD value left NULL - no verified conversion rate for this run.

Key facts

• Announced Jul 31, 2026
• Deal type Licensing/Option
• Therapeutic area Oncology

Related deals

• AstraZeneca PLC / Daiichi Sankyo Company, Limited (2019)
• Novartis AG / Endocyte, Inc. (2018)
• Astellas Pharma Inc. / Seagen Inc. (2009)
• Bristol-Myers Squibb Company / Medarex Inc. (2009)
• Servier / Agios Pharmaceuticals (oncology) (2020)
• Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. (2020)

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Oncology deals